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AbstrACt
Objective The main objective of the study was to 
investigate major differences among European countries 
in implementing infection prevention and control (IPC) 
measures and reasons for reduced compliance.
Design An online survey including experts in IPC and a 
gap analysis were conducted to identify major limitations 
in implementing IPC guidelines.
setting Europe.
Main outcome measures Four areas were targeted: 
(1) healthcare structure, (2) finances, (3) culture and (4) 
education and awareness. Perceived compliance to IPC 
measures was classified as low (<50%), medium (50% to 
80%) and high (>80%). Countries were classified in three 
regions: North-Western Europe (NWE), Eastern Europe (EE) 
and Southern Europe (SE).
results In total, 482 respondents from 34 out of 44 
(77.3%) European countries participated. Respondents 
reported availability of national guidelines to control 
multidrug-resistant Gram-negatives (MDR-GN) in 
20 countries (58.0%). According to participants, 
compliance with IPC measures ranged from 
17.8% (screening at discharge) to 96.0% (contact 
precautions). Overall, three areas were identified 
as critical for the compliance rate: (1) number of 
infection control staff, (2) IPC dedicated educational 
programmes and (3) number of clinical staff. 
Analysis of reasons for low compliance showed high 
heterogeneity among countries: participants from NWE 
and SE deemed the lack of educational programmes 
as the most important, while those from EE considered 
structural reasons, such as insufficient single bed 
rooms or lacking materials for isolation, as main 
contributors to the low compliance.
Conclusions Although national guidelines to reduce the 
spread of MDR-GN are reported in the majority of the 
European countries, low compliance with IPC measures 
was commonly reported. Reasons for the low compliance 
are multifactorial and vary from region to region. Cross-
country actions to reduce the spread of MDR-GN have to 
consider structural and cultural differences in countries. 
Locally calibrated interventions may be fruitful in the 
future.
bACkgrOunD
The global increase of healthcare-associated 
infections (HAI) presents a growing concern 
in healthcare worldwide. According to the 
European Centre for Disease Prevention 
and Control (ECDC), the annual number 
of HAI exceeds 2.6 million and produces the 
highest estimated amount of disability-adjust-
ed-life-years, surpassing all other reported 
communicable diseases in the European 
Union and European Economic Area.1 Multi-
drug-resistant Gram-negative (MDR-GN) 
bacteria have become increasingly common 
as a cause for HAI, such as central line-as-
sociated bloodstream infections, wound or 
surgical site infections and catheter-asso-
ciated urinary tract infections.2 3 The US 
National Healthcare Safety Network identi-
fied Gram-negative bacteria as the cause of 
more than 30% of HAI overall, with almost 
70% of all infections due to Gram-negatives 
occurring in the intensive care setting.4These 
infections significantly increase the risk of 
short- and long-term mortality and hospital 
strengths and limitations of this study
 ► By summarising the opinions of almost 500 experts, 
covering ~75% of all European countries, this anal-
ysis on the implementation of infection prevention 
and control (IPC) measures is the most comprehen-
sive in Europe, even though some countries were 
over-represented.
 ► Combining open online survey, direct emailing and 
offering an open booth for attendees at the European 
Congress of Clinical Microbiology and Infectious 
Diseases  conference, this study summarises the 
opinion of a large range of professionals in the field.
 ► The length of the survey may have been perceived 
as an obstacle by IPC professionals, and thus, de-
creased response rate potentially leading to a bias.
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costs.5 Currently, there is no general consensus on the 
most effective infection prevention and control (IPC) 
measures and intervention strategies for controlling 
the spread of MDR-GN in healthcare facilities. The 
implementation of IPC measures at a time when antibi-
otic treatment options are limited, become a particular 
priority for the control of MDR-GN to ensure patient 
safety.2 6 Multiple barriers exist for the implementation 
of IPC measures against MDR-GN,7 such as the many 
different bacterial species involved, the differences in 
mechanisms of resistance and the varying transmission 
dynamics.8 Although stakeholders such as the ECDC 
since many years are working together with the European 
Union and European Economic Area member states to 
increase awareness to the problem and enforce homoge-
neity of infection control measures, a common European 
strategy to deal with the spread of MDR-GN bacteria is not 
yet achieved.8 9 
The European Committee on Infection Control 
(EUCIC) in close cooperation with the European 
Society of Clinical Microbiology and Infectious Diseases 
(ESCMID) study group for nosocomial infections 
launched the STOP-Negative (Reality and limitationS 
of InfecTiOn Prevention and control measures against 
multidrug-resistant Gram-NEGATIVEs) project aiming at 
investigating major differences among European coun-
tries in implementing IPC measures, and understanding 
reasons for reduced compliance.
MethODs
Objectives
The primary objectives of the study were: (1) to investi-
gate major differences among European countries in 
implementing IPC measures and (2) to identify areas for 
improvement. Secondary objectives were: (1) to explore 
differences in defining susceptibility patterns of target 
MDR-GN bacteria and (2) to check availability of national 
guidelines targeting MDR-GN bacteria.
setting and participants
EUCIC is a standing committee, initiated by ESCMID to 
support the global efforts of standardising and harmon-
ising IPC measures across Europe, to foster research 
in IPC and to provide training in IPC. EUCIC has one 
representative from each country, leading a national 
committee of 3 to 9 experts. The committee’s network 
now includes >90% of all Europe. We developed a 15-item 
cross-sectional, self-administered online survey. After 
being piloted among the EUCIC Stop-Negative working 
group, it was sent to the EUCIC national representatives 
by email and was made accessible to the general public 
on the committee’s website. Additionally, during the 
27th European Congress of Clinical Microbiology and 
Infectious Diseases in Vienna, Austria, conference partici-
pants were invited to fill out the electronic questionnaire 
at the EUCIC booth.
survey design, administration and analysis
The survey was created by the EUCIC Stop-Negative 
working group (MB, HH, NM, EP, JR-B, ET, MCV, WZ). 
Questions addressed the availability of country-specific 
guidelines on the prevention of HAI due to MDR-GN 
bacteria, and barriers to successful implementation of 
IPC measures. Participants were asked to select the three 
most important challenges in their hospital/countries, 
which were defined as the most important priorities in 
improving effectiveness and use of guidelines. The ques-
tionnaire is included as an appendix in the supplemen-
tary material. Collected data was analysed using Microsoft 
Excel 2010 and IBM SPSS Statistics V.23.
Classification of MDr-gn
Respondents reporting availability of national or interna-
tional guidelines in their countries were asked to define, 
how the target MDR-GN was defined (in terms of suscep-
tibility pattern). For the purpose of this survey, MDR-GN 
included the following bacteria: carbapenemase-pro-
ducing Pseudomonas aeruginosa, Acinetobacter baumannii 
and Klebsiella spp and carbapenem-resistant P. aeruginosa, 
A. baumannii and Klebsiella spp, according to European 
Committee on Antimicrobial Susceptibility Testing clin-
ical breakpoints.
Perceived compliance with guidelines and gap analysis
Perceived compliance with IPC measures recommended 
by the guidelines was classified as low (<50%), medium 
(50% to 80%) and high (>80%). To investigate low and 
medium levels of compliance respondents were asked to 
select the main reason for limited compliance from the 
following options: staff shortage, structural reasons (ie, 
not enough single bed rooms, not enough material for 
isolation precautions (ie, gloves and gowns)), financial 
reasons (ie, not possible to block beds in multi-bedded 
rooms due to missing reimbursement), cultural reasons/
controversial efficacy (ie, isolation precaution measures 
are not considered relevant or efficient, MDR-GN patho-
gens are not considered virulent, corruption impedes 
implementation of measures, ie, due to cash drain), and 
educational reasons (ie, healthcare-workers do not know 
how to perform IPC measures such as isolation precaution 
measures, proper procedures of wearing and disposing of 
personal protective equipment). The answers were then 
stratified by each respondent’s country of origin and 
separated into three geographical regions, adapted from 
the WHO regions: Eastern Europe (EE), North-Western 
Europe (NWE) and Southern Europe (SE). Respondents 
were asked to identify the three most important require-
ments to improve the effectiveness and/or use of IPC 
measures. Answers were then compared between the 
previously introduced geographical regions.
statistical analyses
For descriptive purposes, arithmetic mean values with SD, 
medians with IQR and cumulative frequencies were calcu-
lated where appropriate. Two-sided p values of less than 
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0.05 were considered to indicate statistical significance. 
Statistical analysis was performed using the SPSS statis-
tical package (SPSS V.21.0, Chicago, Illinois). Sample 
size calculation was performed before distributing the 
questionnaire. The statistical description of the universe 
of reference (ie, European clinical microbiology/infec-
tious diseases/infection control  specialists) according 
to geographical region was based on a previous analysis 
done by ESCMID.10 The sample size to attain a confi-
dence level of 95% and a precision of ±5% was calculated 
as a minimum of 400 respondents.
Patient and public involvement
No patients were involved in the design of the study nor 
its conduction. Neither were patients the target group 
of this study. The public will be informed by ESCMID/
EUCIC newsletters on publication of the study. Publica-
tion will be in an open-access manner.
results
respondents’ characteristics
In total, 482 respondents (40.9% infectious diseases 
specialists, 29.3% clinical microbiologists and 24.5% 
infection control/hospital hygiene specialists) from 34 
European countries (out of 44 countries) took part in the 
survey (table 1).
Classification of MDr-gn
The majority of participants reported resistance to carbap-
enems to be the major classification criterion for all three 
pathogens (table 2). More than half also considered 
cephalosporin resistance in combination with carbap-
enem resistance to classify MDR - P. aeruginosa and Kleb-
siella spp (61.4% and 68.2%, respectively). Less than half 
(39.2%) used cephalosporin resistance as an additional 
classification variable to define MDR A. baumannii. Resis-
tance to aminoglycosides and fluoroquinolones, besides 
resistance to carbapenems and cephalosporins, were 
considered by half of the respondents to define multi-
drug-resistance (table 2).
guidelines for MDr-gn
More than half of the respondents reported that either 
national (101; 58.0%) or local/regional (113; 64.9%) 
guidelines on the prevention of MDR-GN were available 
in their country. Country guidelines for single organisms, 
that is for MDR P. aeruginosa, A. baumannii, and Klebsi-
ella spp were reported by one-third of the respondents 
(27.0%, 32.4% and 37.4%, respectively). National IPC 
guidelines mainly address the general patient population 
(87; 60.2%), rather than focussing on high-risk patients 
(37; 39.8%). When they did, the following patient 
populations were predominantly identified as high-risk: 
intensive-care unit patients (135; 76.7%), immuno-com-
promised patients (111; 63.1%) and haematology-on-
cology patients (110; 62.5%).
Implementation of infection prevention and control measures
The degree of implementing IPC measures varied signifi-
cantly among countries. Contact precaution measures 
and spatial isolation of patients are applied in 96.0% 
(168/175) and 71.3% (124/174) of the centres, respec-
tively. However, regular universal screening at admission 
or discharge for all patients is performed in only 21.7% 
(38/175) and 17.8% (31/174) of the centres, respec-
tively (figure 1). Of those who implemented admission 
screening, 77.0% (134/174) screen high-risk patients and 
21.7% (38/175) screen all patients at admission. Selective 
digestive decolonisation of MDR-GN high-risk patients 
was reported by 30.9% (54/175). Details about drugs and 
Table 1 Countries of origin of respondents (alphabetical order)
Regions North-Western Europe (n) Eastern Europe (n) Southern Europe (n)
Countries Austria (10) Azerbaijan (1) Albania (2)
Belgium (2) Czech Republic (2) Bosnia and Herzegovina (2)
Denmark (10) Georgia (2) Bulgaria (29)
France (81) Hungary (4) Croatia (5)
Germany (13) Latvia (1) Cyprus (5)
Ireland (18) Lithuania (1) Greece (8)
Netherlands (2) Republic of Moldova (2) Israel (2)
Norway (2) Romania (197) Italy (28)
Sweden (1) Slovakia (2) Kosovo (2)
Switzerland (1) Macedonia (1)




Total (% of total respondents) 145 (30.1%) 212 (44.0%) 125 (26.0%)
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modalities were not asked. General antimicrobial stew-
ardship programmes were reported by 73.4% (126/171) 
and programmes specifically targeting high-risk patients 
by 25.7% (28/109) of the respondents.
Perceived compliance with IPC measures
Highest compliance was reported for electronic flagging 
of patients colonised or infected with MDR-GN, enhanced 
environmental cleaning, and different (admission, 
discharge, periodical) forms of screening modalities. On 
the other hand, lowest compliance was reported for staff 
cohorting and patient isolation in multi-bedded rooms 
while blocking neighbouring beds (figure 2).
Main reasons for perceived low compliance
Reasons reported for low compliance varied across coun-
tries and regions (figure 3). NWE and SE indicated lack of 
appropriate IPC education for perceived low compliance 
Table 2 Antibiotics included in the definition of multidrug-resistance for Pseudomonas aeruginosa, Acinetobacter baumannii 
and Klebsiella pneumoniae
Antimicrobial agents Pseudomonas aeruginosa, n (%)
Acinetobacter baumannii, n 
(%) Klebsiella spp, n (%)
Penicillins + beta-lactamase inhibitors 82 (46.6) 64 (36.4) 76 (43.2)
Cephalosporins 108 (61.4) 69 (39.2) 120 (68.2)
Carbapenems 149 (84.7) 147 (83.5) 142 (80.7)
Fluoroquinolones 92 (52.3) 82 (46.6) 87 (49.9)
Aminoglycosides 79 (44.9) 73 (41.5) 77 (43.8)
Monobactams 25 (14.2) NA 29 (16.5)
Phosphonic acid 7 (4.0) NA 6 (3.4)
Polymyxins 43 (24.4) 50 (28.4) 45 (25.6)
Tetracyclines NA 20 (11.4) 21 (11.9)
Trimethoprim/sulfamethoxazole NA 29 (16.5) 25 (14.2)
Cephamycins NA NA 28 (15.9)
Glycylcyclines NA NA 24 (13.6)
Other 3 (1.7) 7 (4.0) 4 (2.3)
Total 176 (100) 176 (100) 176 (100)
NA, not applicable.
Figure 1 Percentage of implementation of IPC measures to reduce the spread of MDR-GN among survey respondents. HCW, 
healthcare worker; HH, hand hygiene; IPC, infection prevention and control; MDR-GN, multidrug-resistant Gram-negatives. 
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with staff cohorting (76.5% in NWE vs 91.7% in SE). In EE 
on the other hand, staff shortage was the main reason for 
perceived low compliance with staff cohorting (81.0%). In 
EE, financial restraints were the major challenge for high 
compliance with screening measures (62.0%), while SE 
and NWE indicated cultural reasons and staff shortage as 
main contributors. Budget restrictions were also reported 
as main reasons for perceived low compliance with isola-
tion precaution measures in NWE and SE (72.5% and 
54.7%, respectively), while structural reasons (lack of 
single rooms) were the main challenge for applying isola-
tion precaution measures in EE (75.0%). Lack of anti-
microbial stewardship programmes were overall mainly 
linked to educational issues (45.5% in NWE, 53.0% in EE 
and 40.0% in SE) (figure 3).
Areas for improvement
Figure 4 summarises suggested areas for improvement. 
Increased IPC staffing (nurses and doctors) in a situation 
with trained staff shortage was cited the most important 
need for IPC improvement in EE and SE (78.4% and 
57.9%, respectively), while adequate financial resources 
for IPC staffing (nurses and doctors) (50.7%) and clinical 
staffing (nurses and doctors) (55.1%) was mentioned in 
NWE. All respondents selected educational programmes 
and training frontline staff as an important area for 
improvement (49.3% in NWE, 40.4% in SE and 44.6% in 
EE). Particularly in SE, a change in the political awareness 
with regards to healthcare management was mentioned 
as another significant need (49.1%). Interestingly, new 
hospital facilities (31.9% in NWE, 21.1% in SE and 13.5% 
in EE) and specific legislation (13.0% in NWE, 12.3% in 
SE and 18.9% in EE) were mentioned less frequently by 
the respondents.
DIsCussIOn
The rise in MDR-GN has prompted healthcare profes-
sionals worldwide to define IPC measures for controlling 
MDR-GN spread, which need to be implemented at local, 
national and international levels.11 With a response rate 
covering 77.3% of all European countries and a number 
of participants exceeding the calculated number neces-
sary to obtain confidence and precision, we reached 
representative coverage of all Europe.
The primary objectives of our study were to investigate 
major differences among European countries in imple-
menting IPC measures and reasons for reduced compli-
ance, as well as to identify areas for improvement. Our 
results show high heterogeneity of compliance for both, 
countries and IPC measures. Participants from NWE and 
SE ranked educational programmes to be most important 
for improving compliance with IPC measures. Respon-
dents from EE reported structural reasons, such as insuf-
ficient single bed rooms or lacking materials for isolation, 
to be the main contributors to low compliance. Certainly, 
individual country (or even regional) characteristics need 
to be taken into consideration when implementing IPC 
practices.12 13
Figure 2 Perceived level of compliance with IPC measures to reduce the spread of MDR-GN among survey respondents. 
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Three areas were identified by respondents as 
critical for compliance: (1) (sufficient) number of 
infection control staff, (2) IPC dedicated educa-
tional programmes and (3) (sufficient) number of 
clinical staff. Not surprisingly, regional differences 
also applied to these critical areas for improvement 
of IPC measures. An overwhelming majority of the 
respondents from EE, where trained health profes-
sionals leave the countries, selected an increase in 
IPC staff as the most important area for improve-
ment. This was also the most frequent response given 
by SE respondents. On the contrary, NWE respon-
dents considered an increase in actual clinical staff 
(nurses and doctors) more important. More IPC staff 
and establishing educational training programmes 
were considered less important by NWE respondents. 
Some differences between regions, however, might be 
due to other underlying differences in hospital and 
personnel structure that were not assessed by our 
survey. For example NWE and SE had lower perceived 
compliance with cohorting staff compared with the 
other regions. However, this might be due to higher 
availability of more individual rooms or a better staff-
to-patient ratio, and therefore less need for cohorting.
Interestingly, the measures most frequently promoted 
by guidelines were not the ones with the highest level of 
compliance; where recommended, contact precaution 
measures had lower levels of compliance compared with 
universal screening of patients at admission, although 
contact precaution measures are obviously far more 
often applied than screening. Where screening is recom-
mended, however, it appears that hospitals are more 
willing to implement it. The fact that some measures are 
perceived more important (or easier to perform) than 
Figure 3 Main reasons for low compliance. HCW, healthcare worker.
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others is most likely influenced by both knowledge and 
personal views. This example shows that implementation 
does not necessarily follow the level of evidence or the 
rationale behind a recommendation. While applying 
contact precaution measures can directly disrupt the 
transmission of pathogens, screening does not change 
transmission without being linked to action, such as 
pre-emptive or subsequent contact or barrier precaution 
measures. Indeed, these results underline the importance 
of education, both pre- and postgraduate, in streamlining 
efforts to prevent the spread of MDR-GN. Therefore, 
stronger international collaboration is needed, focussing 
on validating and agreeing with the most effective IPC 
prevention strategies. In addition to providing evidence-
based guidelines for all countries, implementation strat-
egies should be evaluated for their applicability taking 
into account local organisational and socio-economical 
contexts.
The secondary outcomes of our study were the 
exploration of differences in the definition of suscep-
tibility patterns for classifying MDR-GN bacteria. The 
majority of participants in our survey reported that 
resistance to carbapenems alone was the major classi-
fication criterion for MDR in Gram-negative bacteria. 
Over half of the respondents also considered ceph-
alosporin resistance in combination with carbap-
enem resistance for classifying MDR - P. aeruginosa 
and MDR - Klebsiella spp. Resistance to aminoglyco-
sides and fluoroquinolones, besides carbapenem- and 
cephalosporin resistance, were taken into account by 
half of the respondents in the definition of multi-
drug-resistance. Overall, our results show unexpected 
heterogeneity in classifying of MDR-GN in Europe. 
This is surprising after ECDC published definitions 
on multidrug-resistant, extensively drug-resistant 
and pandrug-resistant pathogens.14 The fact that 
no internationally published recommendation on 
MDR-GN classification was able to override regional 
classification systems, complicates transnational 
communication and finally the control on the spread 
of MDR-GN. Apparently, standardisation not only is 
required on the IPC level, but also on the microbi-
ology level. Although efforts to standardise antimi-
crobial susceptibility testing were largely successful 
in Europe, and worldwide, efforts to standardise the 
classification of MDR in Gram-negative bacteria are 
needed.
Finally, the study aimed to evaluate availability 
of national guidelines targeting MDR-GN bacteria. 
According to our survey, only half of the respondents 
indicated that national guidelines for MDR-GN exist 
in their countries. This highlights the urgency to 
develop and implement IPC guidelines contextual-
ised to national situations that are currently missing. 
The external validity of the results need to be consid-
ered behind the background of local epidemiology 
and country-specific needs that might differ from the 
overall results.
Our study has limitations. First, since this volun-
tary survey was comprised of self-selected participants, 
the opinions might not be entirely representative for a 
country. Second, some countries are overrepresented, 
which may have resulted in a so-called ‘country-effect’, 
where responses from one country have a dispropor-
tionally large effect on the overall position of the region. 
This holds true for an overrepresentation of Romania for 
EE (table 1). Additionally, we did not take into account 
high or low endemicity settings, which might influence 
screening decisions and compliance with such measures, 
since screening is likely to depend on perceived popu-
lation prevalence, and low application may not be inter-
preted as non-compliance. Third, the elements for 
compliance depicted in figure 1 might not be neces-
sarily advised in all countries. Participants, however, were 
invited to comment and feel that the introduction of bias 
regarding to this might be negligible.
Figure 4 Most important areas for improving compliance with IPC measures to reduce the spread of MDR-GN stratified by EU 
regions. EU, European Union; IPC, infection prevention and control; MDR-GN, multidrug-resistant Gram-negatives.
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COnClusIOns
Our findings revealed high heterogeneity in European 
countries in terms of implementation of IPC measures 
to reduce the spread of MDR-GN. Low compliance 
with recommendations has different reasons, which are 
strongly linked to national and regional contexts. Thus, 
implementation strategies for IPC need to take into 
account culture, educational and socio-economical differ-
ences and financial capacities among European countries. 
The spread of MDR-GN is a global health challenge that 
requires a joint international effort. Our results provide 
guidance for identification of areas of improvement with 
regards to international collaboration, which may help to 
plan joint interventions in Europe to contain the spread 
of MDR-GN.
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